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Prehemodialysis and hemodialysis patients are at an
increased risk of hepatitis B infection and have an impaired
immune response to hepatitis B vaccines. We evaluated
the immune response to the new adjuvant of hepatitis B
vaccine AS04 (HBV-AS04) in this population. We measured
antibody persistence for up to 42 months, and the
anamnestic response and safety of booster doses in patients
who were no longer seroprotected. The primary vaccination
study showed that HBV-AS04 elicited an earlier antibody
response and higher antibody titers than four double doses
of standard hepatitis B vaccine. Seroprotection rates were
significantly higher in HBV-AS04 recipients throughout the
study. The decline in seroprotection over time was
significantly less in the HBV-AS04 group with significantly
fewer primed patients requiring a booster dose over the
follow-up period. Solicited/unsolicited adverse events were
rare following booster administration. Fifty-seven patients
experienced a serious adverse event during the follow-up;
none of which was vaccine related. When HBV-AS04 was
used as the priming immunogen, the need for a booster dose
occurred at a longer time compared to double doses of
standard hepatitis B vaccine. Hence, in this population, the
HBV-AS04 was immunogenic, safe, and well-tolerated both
as a booster dose after HBV-AS04 or standard hepatitis B
vaccine priming.
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Blood has long been recognized as a major vehicle for the
transmission of the hepatitis B virus (HBV). As the process of
hemodialysis requires repeated, prolonged exposure of blood
in the extracorporeal circuit, chronic hemodialysis patients
are at high risk for infection. Furthermore, patients with end-
stage renal disease (ESRD), whether predialysis or chronic
dialysis, are immunodeficient, rendering them at increased
susceptibility to infection and subsequent disease. Approxi-
mately 30–60% of infected hemodialysis patients are unable
to clear the virus and become chronic carriers of HBV,1
remaining infectious, and creating a reservoir for transmission
of new infections. Universal infection control precautions,
including separate rooms and separate machines for patients
with blood-borne diseases, have sharply reduced the incidence
of HBV infection in dialysis units. In addition, HBV vaccination
has been recommended for all seronegative dialysis patients and
staff members since the early 1980s.2 However, the cellular
immunodeficiency in ESRD patients impairs not only the
elimination of HBV but also the immunoresponsiveness to
HBV vaccine. Patients with ESRD show lower seroconversion
rates than healthy immunocompetent subjects. Moreover, after
completion of the vaccination schedule, antibody titers of
responder dialysis patients are low and fall rapidly. Different
approaches have been used to overcome the non-responsiveness
of chronic uremic patients, including different schedules,3 the
intramuscular administration of multiple doses or double
doses,4 the coadministration of zinc or immunomodulators
such as g-interferon,5 levamisole,6 thymopentin,7 interleukin-2,8
and the intradermal administration of HBV vaccine.9 Whenever
feasible, it is preferable for patients with chronic kidney disease
(CKD) to undergo vaccination in the early stages of renal
disease when the primary immune response is still intact.
Thereafter, regular monitoring to ensure the persistence of
protective antibody titers (X10 mIU ml1) is needed as CKD
progresses.10–12
A primary vaccination study (0-, 1-, 2-, and
6-month schedule) in patients with ESRD who were either
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prehemodialysis or undergoing hemodialysis showed
that HBV vaccine formulated with a new adjuvant system
(HBV-AS04, FENDrix, GlaxoSmithKline Biologicals,
Rixensart, Belgium) composed of aluminum salt and MPL
(3-O-desacyl-40-monophosphoryl lipid A) elicited earlier
antibody response and higher antibody titers than
four double doses of standard HBV vaccine, Engerix-B
(GlaxoSmithKline Biologicals).13 We report the results of the
follow-up study that evaluated antibody persistence and the
anamnestic response and safety of HBV-AS04 booster doses
up to 42 months after the initial vaccination.
RESULTS
Study population characteristics
Table 1 shows the number of patients who returned for
follow-up visits and those included in the According to
Protocol (ATP) immunogenicity cohort. Compliance with
participation in long-term blood sampling for antibody
persistence ranged from 70.1 to 80.5% in HBV-AS04
recipients and from 57.9 to 76.3% in standard HBV vaccine
recipients. The high dropout rate over the course of the
extended study was principally linked to the physical
condition of the patients (that is, complications of their
illness prevented their return). None of these events were
determined by investigators to be vaccine or study procedure
related. Other reasons for which patients did not return
included withdrawal of consent (none of which was due to an
adverse event) or the inability to contact study participants
(lost to follow-up). In addition, one study center that was
involved in the primary study did not participate in the study
extension; thus, the 16 patients previously enrolled at this
center did not return. Among the 153 patients who were
enrolled and vaccinated in the primary study, 98 returned for
the HBV-AS04 booster vaccination at month 42.
The proportion of patients on hemodialysis in both
priming groups was greater at month 42 compared to month
0 but remained similar in the two groups (Figure 1). Mean
age of the study population at the time of HBV-AS04 booster
administration was 58.7±14.8 years and the male/female
ratio was 1:0.9. The two priming groups consisted of patients
with age and gender make-up similar to the total population.
Over the full 42 months of follow-up, eight patients (six
HBV-AS04 recipients and two standard HBV vaccine
recipients) were found to be seropositive for antibody to
the hepatitis B core antigen (anti-HBc) at some time point.
Three HBV-AS04 recipients and both standard HBV vaccine
recipients were prehemodialysis. The only hepatitis B surface
antigen (HBsAg)-positive result was found in a prehemodia-
lysis patient at month 7 after completion of the full HBV-
AS04 primary course. Previous and subsequent assays in this
patient were negative for both anti-HBc and HBsAg. Three
participants (two HBV-AS04-primed patients and one
standard HBV vaccine-primed patient) were seropositive
for anti-HBc at month 42. One of the HBV-AS04 recipients
was positive for anti-HBc at all time points beginning with
the primary study, and the remaining two patients were
found to be anti-HBc seropositive beginning at month 24.
None of the three recipients were seropositive for HBsAg. All
anti-HBc-positive samples were HBV DNA negative and thus
allowed us to reasonably rule out the occurrence of HBV
infection during the study.
Antibody persistence
As expected, seroprotection rates decreased over time in both
groups (Figure 2); however, persistence was significantly
higher in the HBV-AS04 group than in the standard HBV
vaccine group at month 30 (84.8 vs 62.5%, P¼ 0.0255),
month 36 (80.4 vs 51.3%, P¼ 0.0057), and month 42 (78.4 vs
51.4%, P¼ 0.0238). No differences were observed in
seroprotection rates in the two groups at all prior time
points, including 1 month following completion of the
immunization course (92.4 vs 87.1%, P¼ 0.2335), month 12
(87.3 vs 78.8%, P¼ 0.1466), and month 24 (89.6 vs 76.2%,
P¼ 0.1466). The observed difference in seroprotection rates
between the two primary vaccine groups became more
pronounced over time, ranging from 13.4% at month 24 to
22.3% at month 30 and 29.1% at month 36. Overall, the
decline in seroprotection rate during the 42-month follow-up
was significantly higher (P¼ 0.0286, from the Generalized
Table 1 | Number of patients returning for the follow-up visits
and number of patients included in the ATP immunogenicity








Month 24 Returning (n) 62 58
Month 30 Returning (n) 60 53
Month 36 Returning (n) 59 50
ATP immunogenicity
cohort month 24–36 (n)
48 43
Month 42 Returning (n) 54 44
ATP immunogenicity
cohort month 42 (n)
37 31
ATP, According to Protocol; HBV, hepatitis B virus; N, number of patients who
completed the primary vaccination course; n, number of patients in each category.
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Figure 1 | Disposition of patients.
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Estimating Equations method) following the standard HBV
vaccine than HBV-AS04. As a result, fewer HBV-AS04-
primed patients required booster vaccination over the
42 months of follow-up: 8 (16.7%) HBV-AS04-primed
patients vs 18 (42.9%) standard HBV vaccine-primed
patients (P¼ 0.0098; Table 2). In addition, more patients
primed with standard HBV vaccine required repeated
boosting during the course of the study than was observed
in HBV-AS04-primed patients (Table 3).
Slightly over one-half (54.1%) of the HBV-AS04-primed
patients and 29% of the standard HBV vaccine-primed
patients exhibited antibody to the HBsAg (anti-HBs)
X100 mIU ml1 42 months after the initial vaccination
(Figure 3); however, the difference did not reach statistical
significance (P¼ 0.0502).
Antibody response to HBV-AS04 booster dose at month 42
A total of 98 patients (54 in the HBV-AS04-primed group
and 44 in the standard HBV vaccine-primed group) returned
and received the month 42 dose of HBV-AS04. This
vaccination represented the fourth booster dose for one patient
(standard HBV vaccine priming), the third booster for four
patients (three in the standard HBV vaccine-primed group and
one in the HBV-AS04-primed group), and the second booster
for 21 patients (14 in the standard HBV vaccine-primed group
and seven in the HBV-AS04-primed group).
At month 42, prior to booster administration, 87.1% of
the standard HBV vaccine-primed patients and 86.5% of the
HBV-AS04-primed patients were seroprotected. At month
43, all HBV-AS04-primed patients and all except one of the
standard HBV vaccine-primed patients exhibited seroprotec-
tive levels of anti-HBs. The observed increase in anti-HBs
geometric mean titers (GMTs) from pre-booster to post-
booster was 64.0-fold in the standard HBV vaccine-primed
group compared with the 199.4-fold increase in the HBV-
AS04-primed group. The anti-HBs GMT elicited 1-month
post-booster vaccination was significantly higher in the HBV-
AS04-primed group (38805.0 mIU ml1) than in the standard
HBV vaccine-primed group (9541.6 mIU ml1) (P¼ 0.0091,
Wilcoxon rank sum test; Figure 4).
All except three month 42 booster recipients demonstrated
a booster effect as defined per protocol. In patients who were
seroprotected at least at one previous time point, only two
did not show a booster effect. Although the HBV-AS04



























Figure 2 | Persistence of anti-HBs seroprotection rates. Fisher
exact test two-sided Po0.05 at all time points except months 7 and
12, which are included for comparison.
Table 2 | Number/percentage of patients requiring a first HBV
booster over the follow-up period (month 24 through month
36)—ATP immunogenicity cohort
Standard HBV vaccine HBV-AS04 vaccine
N n % N n %
Month 24 42 8 19.1 48 1 2.1
Month 30 40 3 7.5 46 3 6.5
Month 36 39 5 12.8 46 3 6.5
Month 42 31 2 6.5 37 1 2.7
ATP, According to Protocol; HBV, hepatitis B virus; N, number of patients in the ATP
immunogenicity cohort with a blood sample available at the given time point; n/%,
number/percentage of patients in the ATP immunogenicity cohort who required a
first booster dose.
Patients who were not seroprotected (anti-HBs titer o10 mIU ml1) at the previous
time point received a dose of HBV-AS04 vaccine as booster.
Table 3 | Summary of booster doses at month 42





All patients who received a booster dose at month 42 68 31 37
Patients receiving a first booster dose at month 42 48 17 31
Patients receiving a second booster dose at month 42 16 10 6
Patients receiving a third booster dose at month 42 3 3 —
Patients receiving a fourth booster dose at month 42 1 1 —
HBV, hepatitis B virus; total, total number of patients with the specified number of boosters in the two groups.






































Figure 3 | Percentage of vaccine recipients with anti-HBs
X100 mIU ml1 over the long-term follow-up. Fisher exact test
two-sided P40.05 for all time points except months 7 and 12
only, which are included for comparison.
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in these patients, both had high month 43 titers (3991
and 34 820 mIU ml1). One standard HBV vaccine-primed
patient did not respond to the primary course or to HBV-
AS04 booster doses given at months 24, 30, and 42.
Reactogenicity and safety of HBV-AS04 booster
Booster doses administered at months 24, 30, and 36
involved sample sizes ranging from 3 to 33 vaccinees.
Although based on these small samples, reactogenicity data
suggest a higher incidence of local injection symptoms than
systemic symptoms with subsequent booster doses of HBV-
AS04 irrespective of priming vaccine (Table 4).
Pain at the injection site was the most frequently reported
solicited local symptom. The percentage of HBV-AS04
booster doses followed by pain at the injection site was
37.5% in the HBV-AS04-primed group, which was com-
parable to the incidence of pain after primary vaccination
with HBV-AS04 (41.0%) observed in the primary study.
Conversely, in the standard HBV vaccine-primed group,
injection site pain was reported more frequently following
the HBV-AS04 booster (52.9%) than the primary course
(13.2%). Only two cases (9.5%) of a grade 3 solicited local
symptom (pain) were reported (both in the standard HBV
vaccine-primed group).
Fatigue was the most frequently reported solicited general
symptom and was reported only in the standard HBV
vaccine-primed group (five patients or 31.3%). Only two
patients reported fever, one in each priming group. One
severe fever (39.21C) was reported (HBV-AS04-primed
group). No other severe solicited general symptoms were
observed.
A total of 10 patients (6 in the standard HBV vaccine-
primed group and 4 in the HBV-AS04-primed group)
reported 15 unsolicited symptoms. Events in three patients
were of grade 3 intensity. None were related to the urinary
system and none were considered vaccine related by
investigators.
Month 42 booster administration involved reactogenicity
and safety data from 97 vaccinees (one patient was lost to
follow-up following vaccination and a documented symptom
sheet was not returned for one patient, both in the standard
HBV vaccine-primed group). Very few grade 3 symptoms
were reported. There were two local injection site cases of
grade 3 pain, one case of grade 3 redness and one case of
grade 3 swelling. The incidence of solicited general symptoms
was low overall and similar in both groups (the most frequent
being fatigue and headache in the standard HBV vaccine-
primed group (11.8%) and fatigue in the HBV-AS04-primed
group (9.8%)). None of the symptoms reported were of
grade 3 intensity. Unsolicited adverse events were reported in
five patients. Grade 3 events were reported in one patient
(renal colic and urethral dilation, and neither was determined
to be vaccine related).
Serious adverse events were reported in a total of 57
patients between month 24 and month 43. Of these, events in
13 patients were fatal. The causes of death were related to the
cardiovascular system or were due to progression of kidney
disease for all except one event that resulted from a motor
vehicle accident. In all cases, investigators reported that there
was no reasonable possibility that the serious adverse event
could have been caused by the vaccine.
DISCUSSION
The primary objective of this study was to evaluate the
persistence of anti-HBs antibodies in subjects who received
either HBV-AS04 or standard HBV vaccine as a primary
vaccination course. Additionally, the immunogenicity and
safety of a booster dose of HBV-AS04 was assessed in patients
who received either HBV-AS04 or standard vaccine as a
primary vaccination course and whose anti-HBs antibody
titers fell below 10 mIU ml1.
Results from the primary study showed that the primary























Figure 4 | Pre- and post-month 42 booster geometric mean
anti-HBs titers.
Table 4 | Incidence and nature of symptoms (solicited/
unsolicited) reported during the 4-day follow-up period after







Priming group N n % n % n %
Dose 5
HBV-AS04 44 23 52.3 9 20.5 19 43.2
Standard HBV vaccine 25 12 48.0 6 24.0 11 44.0
Dose 6
HBV-AS04 7 4 57.1 1 14.3 4 57.1
Standard HBV vaccine 14 10 71.4 5 35.7 8 57.1
Dose 7
HBV-AS04 1 0 0.0 0 0.0 0 0.0
Standard HBV vaccine 3 2 66.7 0 0.0 2 66.7
Dose 8
HBV-AS04 1 0 0.0 0 0.0 0 0.0
Standard HBV vaccine 2 2 100.0 1 50.0 1 50.0
HBV, hepatitis B virus; N, number of patients who received the given dose; n/%,
number/percentage of vaccinees reporting a given adverse event.
Dose 5, dose 6, dose 7, dose 8: 1st, 2nd, 3rd, 4th booster dose, respectively
(irrespective of the time point of booster vaccination).
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induced a faster onset of the immune response. At month 7,
more patients were seroprotected, and from month 3 to
month 7 higher GMTs were obtained in the HBV-AS04 group
than in the standard HBV vaccine group. On the basis
of these observations, primary vaccination with HBV-AS04
was expected to provide a longer persistence of protective
antibody levels. These expectations were confirmed by the
present long-term follow-up study.
This study extension confirms the better persistence of
circulating anti-HBs antibody up to 42 months following
primary vaccination with HBV-AS04. The percentage of
patients still seroprotected at months 30, 36, and 42 was
significantly higher in the group that received a primary
course with HBV-AS04 vaccine than in the standard HBV
vaccine. The number of subjects receiving their first booster
dose at month 42 was higher in the HBV-AS04-primed group
than in the standard HBV vaccine-primed group, reflecting
that more patients primed with the standard vaccine had to
be boosted at earlier time points. Although statistically
significant, the findings must be interpreted with caution
considering that there was no adjustment for multiplicity of
end points and the numerical differences in rates indicate
possible clinically relevant variation in protection.
According to current recommendations by vaccination
advisory bodies such as STIKO in Germany14 and the Joint
Committee in the United Kingdom,15 as well as key opinion
leaders,16,17 a cutoff of 100 mIU ml1 is considered as a
necessary threshold for maintaining protection in immuno-
compromised patients. The number of patients retaining
titersX100 mIU ml1 after primary vaccination tended to be
higher in the HBV-AS04 group than in the standard HBV
vaccine group at months 30, 36, and 42.
Healthy vaccinees who lose circulating antibodies still have
immunologic memory in the form of HBsAg-specific
memory lymphocytes. For this reason, it is widely accepted
that there is no need for booster doses of hepatitis B vaccine
in immunocompetent individuals who have responded to a
primary vaccination course.18 In contrast to healthy subjects,
it cannot be assumed that immunologic memory in
immunocompromised patients, such as those with chronic
renal failure, is robust enough to offer protection if the titer
drops below the recognized protective level. In these patients,
protection relies on circulating antibodies and less on
immune memory. There have indeed been reports of
clinically significant HBsAg-positive infection in dialysis
patients who had lost antibodies.19,20 Therefore, it is widely
accepted that immunocompromised patients need to be
boosted if their anti-HBs titer drops below 10 mIU ml1.14
After administration of the HBV-AS04 dose at month 42
to all patients who completed the primary vaccination
course, a satisfactory booster effect was seen in a majority
of patients. Only one patient (out of 97) had anti-HBs titer
below 10 mIU ml1 1 month post-booster. This patient did
not respond to the standard vaccine primary course and to
HBV-AS04 booster doses given at months 24, 30, and 42. In
patients who were seroprotected at least at one previous time
point, only two did not show a booster effect as defined per
protocol. Although the HBV-AS04 booster did not elicit a
twofold increase in anti-HBs titers in these subjects, it should
be taken into account that both had high anti-HBs titers at
month 43 (3991 and 34 830 mIU ml1). In the same cohort,
the increase in anti-HBs GMTs from pre-booster to post-
booster was 64.0-fold in the standard vaccine-primed group
as compared to a 199.4-fold increase in the HBV-AS04-
primed group.
Impaired immunological response to HBV vaccine among
patients with ESRD has been attributed to multiple
confounding factors, including advanced age, obesity, smok-
ing, anemia, iron loading, erythropoietin deficiency, diabetic
status, uremia, malnutrition, inadequate dialysis, and use of
bioincompatible dialyzers. Evaluation of influencing factors
on immune response in patients with ESRD was not within
the scope of this study in which the primary focus was to
evaluate the need and timing of additional HBV vaccine
booster doses in the target population of prehemodialysis
and hemodialysis patients.
Within the limits of this study (that is, small samples with
as-needed booster doses), the reactogenicity and safety
profile of the HBV-AS04 vaccine administered as a booster
dose in prehemodialysis and hemodialysis patients can be
considered as acceptable. Although reactogenicity data
suggest an increase in the incidence of local injection site
symptoms with subsequent booster doses of HBV-AS04 in
standard HBV vaccine-primed patients, no firm conclusion
regarding this effect was allowed in view of the small samples
afforded by the as-needed booster doses. However, clinically
significant events were rare. Only injection site pain was
reported as grade 3 and occurred in only two standard HBV
vaccine-primed patients. Although at least one serious
adverse event was reported in 57 patients and the event was
fatal in 13 patients over the extended follow-up, none of these
events were determined by the investigators to be related to
the safety of the vaccines.
Two doses of the standard vaccine (a total of 2 ml and
40 mg of the HBsAg antigen) administered according to a 0-,
1-, 2-, and 6-month schedule are recommended for basic
immunization of prehemodialysis and hemodialysis patients.
The AS04-adjuvanted HBV vaccine is administered in
accordance with the same schedule; however, only one dose
is recommended. The applied schedule allows the main-
tenance of higher antibody titers for longer periods of time
than with the standard vaccine. Thus, fewer revaccinations
can be anticipated resulting in overall prolonged HBV
protection at reduced costs.
MATERIALS AND METHODS
Study population and design
The primary study included prehemodialysis (documented creati-
nine clearance p30 ml min1) and hemodialysis patients aged 415
years and who were HBV-naive. Patients were openly randomized
according to a 1:1 ratio to receive either a single dose of HBV-AS04
or a double dose of the standard HBV vaccine (two 1.0 ml
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monodose vials of the vaccine were mixed and given as a single
injection) according to a 0-, 1-, 2-, and 6-month schedule. One dose
(0.5 ml) of HBV-AS04 contained 20 mg of recombinant HBsAg,
50 mg of MPL, and 0.5 mg of aluminum as salt. One dose (1.0 ml) of
the standard HBV vaccine was composed of 20mg of recombinant
HBsAg and 0.5 mg of aluminum as salt.
The open, comparative, long-term extension study was per-
formed at five of the six study sites involved in the primary
vaccination study and included six investigators in three countries
(Czech Republic, Malaysia and Spain). The study protocol was
approved by the respective ethics review committee at each trial
center and was conducted in accordance with the ethical principles
described in the 1996 version of the Declaration of Helsinki
Principles and Good Clinical Practice. All participants gave written
informed consent before they were enrolled. Patients who completed
the primary vaccination course were contacted to participate in the
month 24 extension and similarly for each subsequent study
extension at months 30, 36, and 42.
Blood samples were obtained 24, 30, 36, and 42 months after the
first vaccination and serum was assayed for the presence of
antibodies to HBsAg (anti-HBs) using a commercial enzyme
immunoassay kit (AUSAB, Abbott Laboratories, Chicago, IL,
USA). Antibody concentrations above or equal to the assay cutoff
(3.3 mIU ml1) were considered seropositive; antibody concentra-
tionsX10 mIU ml1 were considered seroprotective. Blood samples
were also assayed for the presence of HBsAg and anti-HBc using
commercial kits (AxSYM HBsAg/Abbott and AxSYM CORE/
Abbott). Results were expressed as positive or negative. Serum
samples with positive anti-HBc results were also tested for the
presence of HBV DNA by PCR.
At months 24, 30, and 36, patients without seroprotective levels of
anti-HBs received a booster dose of HBV-AS04 irrespective of the type
of priming vaccine. Serum samples were obtained for determination
of antibody response to booster administration after 1 month.
Since promising results after HBV-AS04 booster dose adminis-
tration were obtained in the long-term follow-up phase of the study,
the protocol was amended to collect additional data on the antibody
response to a single booster dose of HBV-AS04. All patients who
completed the four-dose primary course were then invited to receive
a HBV-AS04 booster dose at month 42. An anamnestic (booster)
response to booster administration was defined as (a) the recurrence
of seroprotective levels of anti-HBs in patients who had been
seroprotected after the primary vaccination course but who needed
a booster dose because of loss of seroprotective antibody titers and,
at month 43, the definition included (b) a twofold increase in anti-
HBs titers 1 month after the booster dose as compared to the
reference titer pre-booster at month 42, in subjects who were
seroprotected at the said time.
After each booster, all vaccinees were given diary cards for
recording solicited local injection site symptoms (pain, redness,
swelling) and systemic symptoms (headache, fatigue, gastro-
intestinal symptoms, fever) on the day of vaccination and for 3
subsequent days. Fever was defined as an axillary temperature
above 37.4 1C. Any other local or general symptoms and all serious
adverse events were recorded for 30 days after booster administra-
tion. Grade 3 (severe) events were those that prevented normal
activities, including spontaneously painful injection site, redness/
swelling with a diameter over 50 mm, and axillary temperature
above 39 1C.
Data collection at each investigator site was performed using
standardized individual Case Report Forms. Computer checks and
blinded review of patient tabulations were performed to ensure
consistency of Case Report Form completion. Adherence to the
protocol requirements and verification of data generation accuracy
were achieved through monitoring visits to each investigator site.
Statistical methods
Statistical analyses were performed using the SAS software version
8.2 (SAS Institute Inc., Carey, NC, USA) on MS Windows. The GEE
(Generalized Estimating Equations) method was used to analyze
variation in seroprotection rates (the percentage of patients with
anti-HBs titer X10 mIU ml1) at successive points in time.21 Only
patients with serological data for more than one time point were
included in the model. Missing values for serological results were
not imputed.
A two-sided Fisher exact test (a¼ 0.05) was used to compare
seroprotection rates at each phase of the extended follow-up.
However, statistically significant findings must be interpreted with
caution, considering that there was no adjustment for multiplicity of
end points and clinical relevance of difference was not taken into
account.
Although it was not initially planned, anti-HBs data were
also separately tabulated with a cutoff of 100 mIU ml1, the
antibody level recommended for protection of immunocom-
promised individuals by several national authorities and key opinion
leaders.14–17
The anamnestic response to booster administration at month 42
was evaluated by calculation of seroprotection rates and GMTs from
blood sampling performed pre-booster (month 42) and 1-month
post-booster (month 43). GMT calculations were performed by
taking the anti-log of the mean of the log transformation of anti-
HBs antibody titers equal to or above the anti-HBs seropositivity
level. In the persistence analysis, GMTs were calculated in
seropositive patients only (that is, those patients with circulating
anti-HBs levels X3.3 mIU ml1).
Immunogenicity analysis was performed on the ATP cohort,
which included all vaccinated patients who had complied with
protocols for both the primary and booster studies. For the
persistence analysis at all time points, this included subjects who had
not received a booster before that point in time.
For the analysis of the anamnestic response to the booster at
month 42, subjects who had been previously boosted were included,
while inclusion in the ATP cohort also required no abnormal
increase in anti-HBs antibody titers between month 36 and month
42 (for subjects who did not receive a booster dose at month 36).
Abnormal increase in antibody titers was defined as a twofold
increase or more in antibody titer (when the antibody titer at month
36 was X100 mIU ml1) or a fourfold increase or more in antibody
titer (when the antibody titer at month 36 was o100 mIU ml1).
Wilcoxon rank sum test compared month 43 GMTs between
priming groups.
The analysis of reactogenicity was based on the number of
booster recipients reporting symptoms in the two priming groups.
Safety of the HBV-AS04 booster was evaluated based upon the
occurrence and relationship to vaccination of serious adverse events
and the occurrence and severity of unsolicited symptoms reported
within 30 days post-booster.
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